-
1
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group EBCTCG
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365:1687-1717.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
2
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
3
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: The M77001 study group
-
Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
-
4
-
-
33947692030
-
A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer
-
Chan A. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 2007;18:1152-1158.
-
(2007)
Ann Oncol
, vol.18
, pp. 1152-1158
-
-
Chan, A.1
-
5
-
-
0003951396
-
-
Centre for Evidence-Based Medicine: Oxford-Centre for Evidence Based Medicine, Available at, Accessed September 1
-
Phillips B, Ball C, Sackett DL et al. Levels of evidence and grades of recommendation. Centre for Evidence-Based Medicine: Oxford-Centre for Evidence Based Medicine, 2001. Available at http://www.cebm.net/index.aspx?o=1025. Accessed September 1, 2007.
-
(2001)
Levels of evidence and grades of recommendation
-
-
Phillips, B.1
Ball, C.2
Sackett, D.L.3
-
6
-
-
0023873924
-
Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081
-
Kardinal CG, Perry MC, Korzun AH et al. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081. Cancer 1988;61:415-419.
-
(1988)
Cancer
, vol.61
, pp. 415-419
-
-
Kardinal, C.G.1
Perry, M.C.2
Korzun, A.H.3
-
7
-
-
0029916885
-
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
-
Venturini M, Bruzzi P, Del Mastro L et al. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996;14:764-773.
-
(1996)
J Clin Oncol
, vol.14
, pp. 764-773
-
-
Venturini, M.1
Bruzzi, P.2
Del Mastro, L.3
-
8
-
-
0035868615
-
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy
-
Pierga JY, Asselain B, Jouve M et al. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer 2001;91:1079-1089.
-
(2001)
Cancer
, vol.91
, pp. 1079-1089
-
-
Pierga, J.Y.1
Asselain, B.2
Jouve, M.3
-
9
-
-
11144355630
-
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
-
Gennari A, Bruzzi P, Orlandini C et al. Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer 2004;90:962-967.
-
(2004)
Br J Cancer
, vol.90
, pp. 962-967
-
-
Gennari, A.1
Bruzzi, P.2
Orlandini, C.3
-
10
-
-
33646510888
-
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
-
Pacilio C, Morabito A, Nuzzo F et al. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 2006;94:1233-1236.
-
(2006)
Br J Cancer
, vol.94
, pp. 1233-1236
-
-
Pacilio, C.1
Morabito, A.2
Nuzzo, F.3
-
11
-
-
0141786835
-
Liposomal anthracyclines in metastatic breast cancer: Clinical update
-
Rivera E. Liposomal anthracyclines in metastatic breast cancer: Clinical update. The Oncologist 2003;8(suppl 2):3-9.
-
(2003)
The Oncologist
, vol.8
, Issue.SUPPL. 2
, pp. 3-9
-
-
Rivera, E.1
-
12
-
-
11144289529
-
Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies
-
Vail DM, Amantea MA, Colbern GT et al. Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004;31(suppl 13):16-35.
-
(2004)
Semin Oncol
, vol.31
, Issue.SUPPL. 13
, pp. 16-35
-
-
Vail, D.M.1
Amantea, M.A.2
Colbern, G.T.3
-
13
-
-
33745227713
-
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: A multicentre phase II trial
-
Al-Batran SE, Bischoff J, von Minckwitz G et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: A multicentre phase II trial. Br J Cancer 2006;94:1615-1620.
-
(2006)
Br J Cancer
, vol.94
, pp. 1615-1620
-
-
Al-Batran, S.E.1
Bischoff, J.2
von Minckwitz, G.3
-
14
-
-
36849062891
-
Maintenance therapy with PLD following standard chemotherapy for MBC significantly prolongs TTP in a multicenter phase III randomized trial: GEICAM 2001-01 study
-
33s
-
Alba E, Ruiz-Borrego M, Martin M et al. Maintenance therapy with PLD following standard chemotherapy for MBC significantly prolongs TTP in a multicenter phase III randomized trial: GEICAM 2001-01 study. Proc Am Soc Clin Oncol 2007;25(18 suppl):33s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Alba, E.1
Ruiz-Borrego, M.2
Martin, M.3
-
15
-
-
4043084834
-
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer
-
Morabito A, Gattuso D, Stani SC et al. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat 2004;86:249-257.
-
(2004)
Breast Cancer Res Treat
, vol.86
, pp. 249-257
-
-
Morabito, A.1
Gattuso, D.2
Stani, S.C.3
-
16
-
-
3442891820
-
Phase II study of pegylated doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer
-
Alexopoulos A, Karamouzis MV, Stavrinides H et al. Phase II study of pegylated doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004;15:891-895.
-
(2004)
Ann Oncol
, vol.15
, pp. 891-895
-
-
Alexopoulos, A.1
Karamouzis, M.V.2
Stavrinides, H.3
-
17
-
-
0001343239
-
Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer
-
Jones V, Finucane D, Rodriguez R et al. Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol 2000;19: 113a.
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
-
-
Jones, V.1
Finucane, D.2
Rodriguez, R.3
-
18
-
-
0141465129
-
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
-
Rivera E, Valero V, Arun B et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21:3249-3254.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3249-3254
-
-
Rivera, E.1
Valero, V.2
Arun, B.3
-
19
-
-
33748475284
-
Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: A multicentre phase II study
-
Ardavanis A, Mavroudis D, Kalbakis K et al. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: A multicentre phase II study. Cancer Chemother Pharmacol 2006;58:742-748.
-
(2006)
Cancer Chemother Pharmacol
, vol.58
, pp. 742-748
-
-
Ardavanis, A.1
Mavroudis, D.2
Kalbakis, K.3
-
20
-
-
19944426799
-
Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure
-
Martin M, Garcia-Donas J, Casado A et al. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer 2004;5:353-357.
-
(2004)
Clin Breast Cancer
, vol.5
, pp. 353-357
-
-
Martin, M.1
Garcia-Donas, J.2
Casado, A.3
-
21
-
-
36849093172
-
-
A Study of Docetaxel Monotherapy or Doxil®/Caelyx® and Docetaxel in Patients with Advanced Breast Cancer. Available at, Accessed April 4, 2007
-
A Study of Docetaxel Monotherapy or Doxil®/Caelyx® and Docetaxel in Patients with Advanced Breast Cancer. Available at http://www.clinicaltrials. gov/ct/show/NCT00091442. Accessed April 4, 2007.
-
-
-
-
22
-
-
33748196550
-
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis
-
Batist G, Harris L, Azarnia N et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis. Anticancer Drugs 2006;17:587-595.
-
(2006)
Anticancer Drugs
, vol.17
, pp. 587-595
-
-
Batist, G.1
Harris, L.2
Azarnia, N.3
-
23
-
-
0035282073
-
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
-
Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-1454.
-
(2001)
J Clin Oncol
, vol.19
, pp. 1444-1454
-
-
Batist, G.1
Ramakrishnan, G.2
Rao, C.S.3
-
24
-
-
0036142158
-
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicentre trial as first-line therapy of metastatic breast carcinoma
-
Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicentre trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36.
-
(2002)
Cancer
, vol.94
, pp. 25-36
-
-
Harris, L.1
Batist, G.2
Belt, R.3
-
25
-
-
0032949449
-
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group
-
Nabholtz J-M, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1413-1424
-
-
Nabholtz, J.-M.1
Senn, H.J.2
Bezwoda, W.R.3
-
26
-
-
17344390083
-
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
-
Sjöström J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35:1194-1200.
-
(1999)
Eur J Cancer
, vol.35
, pp. 1194-1200
-
-
Sjöström, J.1
Blomqvist, C.2
Mouridsen, H.3
-
27
-
-
24944507764
-
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
-
Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-5551.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5542-5551
-
-
Jones, S.E.1
Erban, J.2
Overmoyer, B.3
-
28
-
-
36849094728
-
Cost-effectiveness of docetaxel compared to paclitaxel in metastatic breast cancer: A UK health economic analysis
-
52s
-
Jones SE, Benedict A, Cameron D et al. Cost-effectiveness of docetaxel compared to paclitaxel in metastatic breast cancer: A UK health economic analysis. Proc Am Soc Clin Oncol 2007;25(18 suppl):52s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Jones, S.E.1
Benedict, A.2
Cameron, D.3
-
29
-
-
36849071643
-
Randomized comparison of weekly or every-3-week nab-paclitaxel vs. every-3-week docetaxel as 1st-line therapy in patients with metastatic breast cancer
-
40s
-
Gradishar WJ, Krasnojon D, Cheporov S et al. Randomized comparison of weekly or every-3-week nab-paclitaxel vs. every-3-week docetaxel as 1st-line therapy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2007;25(18 suppl):40s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Gradishar, W.J.1
Krasnojon, D.2
Cheporov, S.3
-
30
-
-
4644357450
-
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
-
Tabernero J, Climent MA, Lluch A et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-1365.
-
(2004)
Ann Oncol
, vol.15
, pp. 1358-1365
-
-
Tabernero, J.1
Climent, M.A.2
Lluch, A.3
-
31
-
-
21844480293
-
CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
-
6s
-
Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004;22(14 suppl):6s.
-
(2004)
Proc Am Soc Clin Oncol
, vol.22
, Issue.14 SUPPL.
-
-
Seidman, A.D.1
Berry, D.2
Cirrincione, C.3
-
32
-
-
41049083853
-
Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer
-
33s
-
Verril MW, Lee J, Cameron DA et al. Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2007;25(18 suppl): 33s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Verril, M.W.1
Lee, J.2
Cameron, D.A.3
-
33
-
-
20044368229
-
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
-
Del Mastro L, Perrone F, Repetto L et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005; 16:253-258.
-
(2005)
Ann Oncol
, vol.16
, pp. 253-258
-
-
Del Mastro, L.1
Perrone, F.2
Repetto, L.3
-
34
-
-
36849071640
-
Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199
-
6s
-
Sparano JA, Wang M, Martino S et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. Proc Am Soc Clin Oncol 2007;25(18 suppl):6s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Sparano, J.A.1
Wang, M.2
Martino, S.3
-
35
-
-
0037096755
-
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
-
O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-2823.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2812-2823
-
-
O'Shaughnessy, J.1
Miles, D.2
Vukelja, S.3
-
36
-
-
33748755039
-
Detailed analysis of a randomized phase III trial: Can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
-
Leonard R, O'Shaughnessy J, Vukelja S et al. Detailed analysis of a randomized phase III trial: Can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006;17:1379-1385.
-
(2006)
Ann Oncol
, vol.17
, pp. 1379-1385
-
-
Leonard, R.1
O'Shaughnessy, J.2
Vukelja, S.3
-
37
-
-
34247232111
-
Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs T followed by X after progression as first line therapy for patients (pts) with metastatic breast cancer (MBC)
-
18s
-
Beslija S, Obralic N, Basic H et al. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs T followed by X after progression as first line therapy for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006;24(18 suppl):18s.
-
(2006)
Proc Am Soc Clin Oncol
, vol.24
, Issue.18 SUPPL.
-
-
Beslija, S.1
Obralic, N.2
Basic, H.3
-
38
-
-
33751400314
-
Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial
-
20s
-
Soto C, Torrecillas S, Reyes S et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial. Proc Am Soc Clin Oncol 2006;24(18 suppl):20s.
-
(2006)
Proc Am Soc Clin Oncol
, vol.24
, Issue.18 SUPPL.
-
-
Soto, C.1
Torrecillas, S.2
Reyes, S.3
-
39
-
-
5644260284
-
Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival
-
5s
-
Albain KS, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc Am Soc Clin Oncol 2004;22(14 suppl):5s.
-
(2004)
Proc Am Soc Clin Oncol
, vol.22
, Issue.14 SUPPL.
-
-
Albain, K.S.1
Nag, S.2
Calderillo-Ruiz, G.3
-
40
-
-
26444589387
-
Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study
-
24s
-
Chan S, Romieu G, Huober J et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. Proc Am Soc Clin Oncol 2005;23(16 suppl):24s.
-
(2005)
Proc Am Soc Clin Oncol
, vol.23
, Issue.16 SUPPL.
-
-
Chan, S.1
Romieu, G.2
Huober, J.3
-
41
-
-
1242329822
-
Platinum-based chemotherapy in metastatic breast cancer: Current status
-
Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat Rev 2004;30:53-81.
-
(2004)
Cancer Treat Rev
, vol.30
, pp. 53-81
-
-
Decatris, M.P.1
Sundar, S.2
O'Byrne, K.J.3
-
42
-
-
4944267230
-
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group
-
Fountzilas G, Kalofonos HP, Dafni U et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004;15:1517-1526.
-
(2004)
Ann Oncol
, vol.15
, pp. 1517-1526
-
-
Fountzilas, G.1
Kalofonos, H.P.2
Dafni, U.3
-
43
-
-
0033821441
-
Gemcitabine and Vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group
-
Nicolaides C, Dimopoulos MA, Samantas E et al. Gemcitabine and Vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2000; 11:873-875.
-
(2000)
Ann Oncol
, vol.11
, pp. 873-875
-
-
Nicolaides, C.1
Dimopoulos, M.A.2
Samantas, E.3
-
44
-
-
0037368197
-
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: A phase I-II study
-
Morabito A, Filippelli G, Palmeri S et al. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: A phase I-II study. Breast Cancer Res Treat 2003;78:29-36.
-
(2003)
Breast Cancer Res Treat
, vol.78
, pp. 29-36
-
-
Morabito, A.1
Filippelli, G.2
Palmeri, S.3
-
45
-
-
0037974853
-
Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study
-
Rossi E, Perrone F, Labonia V et al. Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study. Oncology 2003;64:479-480.
-
(2003)
Oncology
, vol.64
, pp. 479-480
-
-
Rossi, E.1
Perrone, F.2
Labonia, V.3
-
46
-
-
33847138943
-
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
-
Martín M, Ruiz A, Muñoz M et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-225.
-
(2007)
Lancet Oncol
, vol.8
, pp. 219-225
-
-
Martín, M.1
Ruiz, A.2
Muñoz, M.3
-
47
-
-
34548225937
-
A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report
-
42s
-
Mavroudis D, Ardavanis A, Boukovinas I et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report. Proc Am Soc Clin Oncol 2006;24(18 suppl):42s.
-
(2006)
Proc Am Soc Clin Oncol
, vol.24
, Issue.18 SUPPL.
-
-
Mavroudis, D.1
Ardavanis, A.2
Boukovinas, I.3
-
48
-
-
34548188179
-
Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine
-
42s
-
Thomas E, Perez EA, Mukhopadhyay P et al. Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. Proc Am Soc Clin Oncol 2006; 24(18 suppl):42s.
-
(2006)
Proc Am Soc Clin Oncol
, vol.24
, Issue.18 SUPPL.
-
-
Thomas, E.1
Perez, E.A.2
Mukhopadhyay, P.3
-
49
-
-
36749009203
-
Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes
-
33s
-
Vahdat LT, Thomas E, Li R et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. Proc Am Soc Clin Oncol 2007;25(18 suppl):33s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Vahdat, L.T.1
Thomas, E.2
Li, R.3
-
50
-
-
19944429759
-
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer
-
Welt A, von Minckwitz G, Oberhoff C et al. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005;16:64-69.
-
(2005)
Ann Oncol
, vol.16
, pp. 64-69
-
-
Welt, A.1
von Minckwitz, G.2
Oberhoff, C.3
-
51
-
-
33645640366
-
Capecitabine/vinorelbine: An effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer
-
Nole F, Catania C, Munzone E et al. Capecitabine/vinorelbine: An effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer 2006;6:518-524.
-
(2006)
Clin Breast Cancer
, vol.6
, pp. 518-524
-
-
Nole, F.1
Catania, C.2
Munzone, E.3
-
52
-
-
0034082923
-
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients
-
Nagourney RA, Link JS, Blitzer JB et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000;18:2245-2249.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2245-2249
-
-
Nagourney, R.A.1
Link, J.S.2
Blitzer, J.B.3
-
53
-
-
20044364346
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
-
(2005)
J Clin Oncol
, vol.23
, pp. 792-799
-
-
Miller, K.D.1
Chap, L.I.2
Holmes, F.A.3
-
54
-
-
30544455226
-
A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100)
-
Miller KD, Wang M, Gralow J et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94(suppl 1):S6.
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Miller, K.D.1
Wang, M.2
Gralow, J.3
-
55
-
-
15544391142
-
Angiogenesis of breast cancer
-
Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23:1782-1790.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1782-1790
-
-
Schneider, B.P.1
Miller, K.D.2
-
56
-
-
33746591262
-
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
-
Morabito A, De Maio E, Di Maio M et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. The Oncologist 2006;11:753-764.
-
(2006)
The Oncologist
, vol.11
, pp. 753-764
-
-
Morabito, A.1
De Maio, E.2
Di Maio, M.3
-
57
-
-
20844456577
-
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
-
von Minckwitz G, Jonat W, Fasching P et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;89:165-172.
-
(2005)
Breast Cancer Res Treat
, vol.89
, pp. 165-172
-
-
von Minckwitz, G.1
Jonat, W.2
Fasching, P.3
-
58
-
-
23944464495
-
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
-
Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23:5323-5333.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5323-5333
-
-
Baselga, J.1
Albanell, J.2
Ruiz, A.3
-
59
-
-
0038700004
-
Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer
-
Winer E, Cobleigh M, Dickler M et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S115.
-
(2002)
Breast Cancer Res Treat
, vol.76
, Issue.SUPPL. 1
-
-
Winer, E.1
Cobleigh, M.2
Dickler, M.3
-
60
-
-
0042804495
-
Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER negative breast cancer: Results from a phase II study
-
Robertson JFR, Gutteridge E, Cheung KL et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER negative breast cancer: Results from a phase II study. Proc Am Soc Clin Oncol 2003;22:7.
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 7
-
-
Robertson, J.F.R.1
Gutteridge, E.2
Cheung, K.L.3
-
61
-
-
33745277110
-
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
-
Ciardiello F, Troiani T, Caputo F et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006;94:1604-1609.
-
(2006)
Br J Cancer
, vol.94
, pp. 1604-1609
-
-
Ciardiello, F.1
Troiani, T.2
Caputo, F.3
-
62
-
-
0043198131
-
Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?
-
Als-Nielsen B, Chen W, Gluud C et al. Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? JAMA 2003;290:921-928.
-
(2003)
JAMA
, vol.290
, pp. 921-928
-
-
Als-Nielsen, B.1
Chen, W.2
Gluud, C.3
-
63
-
-
0036554731
-
Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer
-
Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-1067.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1061-1067
-
-
Coon, J.S.1
Marcus, E.2
Gupta-Burt, S.3
-
64
-
-
34447314153
-
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III trial
-
Di Leo A, Tanner M, Desmedt C et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III trial. Ann Oncol 2007;18:997-1003.
-
(2007)
Ann Oncol
, vol.18
, pp. 997-1003
-
-
Di Leo, A.1
Tanner, M.2
Desmedt, C.3
-
65
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
-
66
-
-
33847136743
-
Triple-negative breast cancer: Therapeutic options
-
Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: Therapeutic options. Lancet Oncol 2007;8:235-244.
-
(2007)
Lancet Oncol
, vol.8
, pp. 235-244
-
-
Cleator, S.1
Heller, W.2
Coombes, R.C.3
-
67
-
-
4944229642
-
Hallmarks of 'BRCAness' in sporadic cancers
-
Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 814-819
-
-
Turner, N.1
Tutt, A.2
Ashworth, A.3
-
68
-
-
36849035177
-
Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple negative breast cancers?
-
Petit T, Wilt M, Rodier J et al. Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple negative breast cancers? Proc Am Soc Clin Oncol 2007;25(18 suppl):580.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 SUPPL.
, pp. 580
-
-
Petit, T.1
Wilt, M.2
Rodier, J.3
|